Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.

Victoria Federico Paly Yusuke HikichiTimothy BakerEijun ItakuraNisha ChandranJames Harrison

Published in: Journal of medical economics (2020)

This analysis indicates that adding ipilimumab to nivolumab therapy represents a cost-effective new treatment option for patients with unresectable malignant melanoma in Japan.

Keyphrases

locally advanced
squamous cell carcinoma
radiation therapy
combination therapy
replacement therapy
data analysis